Novo Nordisk China announced the launch of the China Essentials program — the guidelines to integrate China into Novo Nordisk’s global clinical development program and achieve simultaneous submission for global new drug applications.
The program aims to boost Novo Nordisk’s research and development capability and accelerate innovative drug registration in China, so Chinese patients can benefit from their latest global innovations.
Additionally, the company will initiate a strategic partnership with Chinese hospitals and strengthen academic exchanges with Chinese healthcare professionals to improve their clinical research capabilities.
Following the guidelines, Novo Nordisk will file the Clinical Trial Application of new pipeline products simultaneously in China and globally for the first time.
It plans to establish strategic partnerships with 20 hospitals nationwide by 2021, expanding their network of clinical trial bases...
Full text at GMPnews.Net